SAVE MONEY ON TRAVEL DEALS

Researchers at the University of Pennsylvania School of Medicine and colleagues at Sangamo BioSciences Inc. of Richmond, Calif., said their goal is to use modified T cells from an HIV-infected person for that person's own treatment. They showed that, by using the zinc fingers, they could reduce the viral load of immune-deficient mice transplanted with engineered T cells.

The researchers, led by Dr. Elena Perez, an assistant professor of pediatrics, and Dr. Carl June, a professor of pathology and laboratory medicine at Penn, are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene -- necessary for the AIDS virus to enter immune system cells -- deliberately knocked out.

The modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.

The research is reported online in the journal Nature Biotechnology.

 BREAKING STORIES

Home warning system for cardiac patients

African-American COPD links to lung cancer

Pussycat Dolls wow Fashion Rocks

West Nile virus claims 3rd Californian

Jesse Jackson Sr. released from hospital

Failed anxiety drug may fight cancer

Test could lead to better BSE detection

Universal flu vaccine tested on humans

Clues to treat brain cancer discovered

Cigarettes' attraction may not nicotine

Breakfast protein may help in weight loss

Nursing mothers with MRSA can be treated

Sexy Mendes billboard graces Times Square

Intensive care unit can traumatize kids

Coroner: Mysterious deaths were natural

Family fights over woman's life support

Quercetin, found in produce, fights flu

2.4 million smoking-linked cancers 1999/04

FDA approves hepatitis B viral DNA test

Scientists ID Ebola cell-invasion strategy